Oragenics shows ONP-002 stable across wide temperature range

Oragenics announced its lead candidate for treating concussion, ONP-002, is stable across a wide temperature range, eliminating the need for cumbersome cold storage for the drug device combination. ONP-002 is a new chemical entity designed to target the brain through a breath propelled delivery system into the nasal cavity to treat concussions. Oragenics recently completed the synthesis of its ONP-002 drug batch for the planned Phase II clinical trial. The company reports 3-month stability with over 99% purity at temperatures ranging from -20 degrees C to 104 degrees C. Oragenics is confident in its belief that ONP-002 will not require cumbersome cold chain protocols during transport and storage, maintaining its chemical structure and function even in extreme temperatures.